
Jules Mitchel  of Target Health discusses, his views on its importance of risk-based monitoring in the clinical trials industry, now that is such a popular topic.

Risk-Based Monitoring – Part Two In Depth Review

Increasing Intensity of On-Site Monitoring a Troubling Trend

Industry Metric Indicates Low ROI with Full Source Document Verification

Has FDA Guidance on Risk-based Monitoring Impacted SDV Coverage Yet?

News

Jules Mitchel of Target Health discusses risk-based monitoring trends in the clinical trials industry